Genom Biotech Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
- Paid Up Capital ₹ 7.85 Cr
- Company Age 25 Year, 3 Days
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 34.38 Cr
- Satisfied Charges ₹ 7.70 Cr
- Revenue Growth 27.32%
- Profit Growth -12.07%
- Ebitda -7.63%
- Net Worth -12.37%
- Total Assets -8.79%
About Genom Biotech
Genom Biotech Private Limited (GBPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 January 2000 and has a history of 25 years. Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 7.85 Cr.
The company currently has active open charges totaling ₹34.38 Cr. The company has closed loans amounting to ₹7.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Nashik, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239MH2000PTC123931
-
Company No.
123931
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Jan 2000
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Genom Biotech Private Limited offer?
Genom Biotech Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Injection, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Cardiac Drugs, Antibiotic Tablets & Capsules, Ciprofloxacin Tablets, Anti Infective API, Kidney Drugs, Hydrochlorothiazide Tablets.
Who are the key members and board of directors at Genom Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raunit Rathor
|
Director | 27-Oct-2018 | Current |
Singh Sheila
|
Director | 01-Jun-2019 | Current |
|
Managobinda Dalai
|
Director | 10-May-2021 | Current |
Financial Performance of Genom Biotech.
Genom Biotech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 27.32% increase. The company also saw a substantial fall in profitability, with a 12.07% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genom Biotech?
In 2020, Genom Biotech had a promoter holding of 70.00% and a public holding of 30.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Clestra Life Sciences Private LimitedRaunit Rathor and Managobinda Dalai are mutual person
Charges (Loans)
₹34.38 Cr
₹7.70 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 26.43 Cr
- Hdfc Bank Ltd. : 3.50 Cr
- Vijaya Bank : 3.25 Cr
- State Bank Of India : 0.95 Cr
- B.K.C. : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Mar 2005 | Vijaya Bank | ₹3.00 Cr | Open |
| 09 Mar 2005 | Vijaya Bank | ₹2.50 M | Open |
| 01 Jan 2005 | B.K.C. | ₹2.50 M | Open |
| 31 May 2004 | Hdfc Bank Ltd. | ₹3.50 Cr | Open |
| 03 Apr 2004 | Bank Of India | ₹13.51 Cr | Open |
How Many Employees Work at Genom Biotech?
Genom Biotech has a workforce of 5 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genom Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genom Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
